Omacor® (a concentrated preparation of omega-3-acid ethyl esters that contains 46% eicosapentaenoic acid (EPA) ethyl ester and 38% docosahexaenoic acid (DHA) ethyl ester) is indicated as an adjuvant treatment in secondary prevention after myocardial infarction in addition to other standard therapy. Omacor® is also indicated for the treatment of endogenous hypertriglyceridaemia as a supplement to diet, when dietary measures alone are insufficient to produce an adequate response.
|11/02/2013||19/04/2013||Reimbursement Not Recommended|
The NCPE believe that Omacor® is not a cost-effective adjuvant treatment for patients post-myocardial infarction in the Irish Healthcare Setting. The cost effectiveness of Omacor® for treatment of endogenous hypertriglyceridaemia as a supplement to diet has not been demonstrated.